3 min read
Product Launch Readiness Zürich
Join Us for an Exclusive Conference on Product Launch Readiness - Zürich, 10th April 2025, 17:00 CEST
2 min read
Accelerating Operational Excellence and Client Success
SOUTHBOROUGH, MA – October 30, 2024—Veristat, a scientific-minded global clinical research organization (CRO) and consultancy, announced the appointment of Kim McLean Boericke as its Chief Operating Officer to lead the company’s global delivery and consultancy teams.
Kim brings over 25 years of experience to Veristat, having served in executive leadership roles driving and accelerating delivery of drug development programs across the pharma services industry. She is a champion of patients driving accessibility of and inclusion in clinical trials. Among her various responsibilities, she will drive and accelerate Veristat’s day-to-day operations globally, ensuring quality, timely, and harmonized service delivery across all stages of the product lifecycle management.
This is an evolutionary time for Veristat as we take on increasing responsibilities to power a deeper level of client engagement and complex problem-solving,” stated Patrick Flanagan, Chief Executive Officer for Veristat. “I am excited about what Kim will bring to Veristat’s clients. She has had a storied journey through our industry. She has great experience, having designed, built, and restructured organizations throughout her career. I look forward to working closely with Kim to sharpen Veristat’s ability to deliver high-quality, insightful services to our clients and the patients they serve."
A graduate of Duke University with a degree in biology, author of more than 15 published scientific and business articles, and former board member for MAPI Trust, Kim has been an engaged leader in the industry focusing on reducing clinical trial burden and removing barriers for patients and sites while accelerating delivery of complex clinical projects for her clients. Most recently, Kim was COO at Thread where she led the professional services team of clinical services, technology enablement, and patient-centered operations. Kim previously held executive-level positions at ICON, IQVIA, ClinTrials, INC Research, Duke Clinical Research Institute, and i3 Research, playing pivotal roles advising, planning and delivering drug development programs, consistently exceeding growth targets while improving team member productivity.
I am fully committed to building on Veristat’s success to grow and globalize our team to accelerate delivery and achievement of our programs with quality,” stated Kim Boericke. “I believe our global team’s expertise and passion, along with our flexible execution approach, will enable our clients to bring novel compounds to the market. I look forward to mentoring our talented global teams to create operational efficiencies inspired by innovative scientific insight to boost the speed at which our clients will be able to bring these therapies to patients.”
Kim’s appointment at Veristat aligns with the Company’s 30th year, strengthening the organization at the executive level and spearheading its transformation by accelerating global clinical trials to bring novel treatments to patients faster.
About Veristat
Veristat is a global CRO and Consultancy that integrates full-service clinical trial delivery, regulatory affairs and safety, and strategic advice to accelerate the development, approval, and commercialization of novel therapies around the globe. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, Veristat experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.
Veristat's focus on novel drug development has led to success when handling any unknown that arises, from the simplest to the most complex, across numerous therapeutic areas, including rare/ultra-rare disease, advanced therapies, oncology, and biologics. Sponsors partner with Veristat experts who care—like they do—to improve patients’ lives.
Veristat Contact:
Gillian Dellacioppa, Director, Marketing Strategy & Content, Veristat
media@veristat.com